| Market Cap | 768.87M | P/E | - | EPS this Y | 128.70% | Ern Qtrly Grth | - |
| Income | 48.16M | Forward P/E | 8.76 | EPS next Y | 24.40% | 50D Avg Chg | - |
| Sales | 566.77M | PEG | 21.44 | EPS past 5Y | 26.50% | 200D Avg Chg | -5.00% |
| Dividend | N/A | Price/Book | 4.23 | EPS next 5Y | 0.55% | 52W High Chg | -27.00% |
| Recommedations | 2.20 | Quick Ratio | 1.07 | Shares Outstanding | 32.71M | 52W Low Chg | 43.00% |
| Insider Own | 1.41% | ROA | 10.28% | Shares Float | 28.80M | Beta | 1.05 |
| Inst Own | 122.15% | ROE | 24.68% | Shares Shorted/Prior | 6.99M/7.01M | Price | 22.00 |
| Gross Margin | 85.93% | Profit Margin | 8.50% | Avg. Volume | 289,588 | Target Price | 40.00 |
| Oper. Margin | 41.20% | Earnings Date | May 9 | Volume | 198,938 | Change | -3.38% |
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
| Needham | Buy | Apr 11, 24 |
| Truist Securities | Buy | Feb 26, 24 |
| Piper Sandler | Overweight | Feb 23, 24 |
| Needham | Buy | Feb 2, 24 |
| Needham | Buy | Jan 4, 24 |
| Truist Securities | Buy | Jan 4, 24 |
| Jefferies | Hold | Jan 4, 24 |
| Needham | Buy | Aug 25, 23 |
| HC Wainwright & Co. | Neutral | Aug 4, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Ciaffoni Joseph | President and CEO President and CEO | Dec 18 | Sell | 30.16 | 68,768 | 2,074,043 | 275,000 | 12/20/23 |
| Ciaffoni Joseph | President and CEO President and CEO | Dec 18 | Option | 21.34 | 68,768 | 1,467,509 | 301,454 | 12/20/23 |
| Heffernan Michael Thomas | Director Director | Dec 22 | Sell | 23.45 | 25,041 | 587,211 | 28,023 | 12/27/22 |
| Heffernan Michael Thomas | Director Director | Dec 22 | Option | 16.15 | 25,041 | 404,412 | 31,843 | 12/27/22 |
| Ciaffoni Joseph | President and CEO President and CEO | Dec 22 | Sell | 23.46 | 2,461 | 57,735 | 248,750 | 12/27/22 |
| Heffernan Michael Thomas | Director Director | Dec 19 | Option | 16.15 | 83,964 | 1,356,019 | 74,623 | 12/21/22 |
| Heffernan Michael Thomas | Director Director | Dec 19 | Sell | 23.08 | 83,964 | 1,937,889 | 28,023 | 12/21/22 |
| Ciaffoni Joseph | President and CEO President and CEO | Dec 19 | Sell | 23.06 | 17,842 | 411,437 | 251,211 | 12/21/22 |
| Ciaffoni Joseph | President and CEO President and CEO | Dec 01 | Option | 15.9 | 76,653 | 1,218,783 | 400,106 | 12/05/22 |
| Ciaffoni Joseph | President and CEO President and CEO | Dec 01 | Sell | 22.77 | 131,053 | 2,984,077 | 269,053 | 12/05/22 |
| Ciaffoni Joseph | President and CEO President and CEO | Nov 28 | Option | 15.9 | 43 | 684 | 323,496 | 11/30/22 |
| Ciaffoni Joseph | President and CEO President and CEO | Nov 28 | Sell | 22 | 43 | 946 | 323,453 | 11/30/22 |
| Ciaffoni Joseph | President and CEO President and CEO | Nov 22 | Option | 15.9 | 65 | 1,034 | 323,518 | 11/25/22 |
| Ciaffoni Joseph | President and CEO President and CEO | Nov 22 | Sell | 22 | 65 | 1,430 | 323,453 | 11/25/22 |
| Kuhlmann Shirley R. | EVP and General Coun.. EVP and General Counsel | Aug 11 | Sell | 20.01 | 300 | 6,003 | 148,084 | 08/15/22 |